

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/26161

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 31/44,19
US CL : 514 575,357,352
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
U.S. : 514 575,357,352

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
STN: SAHA, SAHA structure, EAST: SAHA, cancer, anticancer, tumor, tumour, neoplasia, neoplasm.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y,P	US 2004/0116407 A1 (BORISY et al) 17 June 2004 (17.06.2004), whole document	1-111
Y,P	US 6,811,788 B2 (YU) 2 November 2004 (02.11.2004) whole document	1-111
Y	US 2002/0044919 A1 (YU) 18 April 2002 (18.04.2002) Whole document	1-111
Y,P	US 2003/0235588 A1 (RICHON et al) 25 December 2003 (25.12.2003) whole document	1-111
Y	US 2003/0059812 A1 (RICHON et al) 27 March 2003 (27.03.2003) whole document	1-111
Y	US 5,369,108 (BRESLOW et al) 29 November 1994 (29.11.1994) Whole document	1-111
Y	US 6,511,990 B1 (BRESLOW et al) 28 January 2003 (28.01.2003), whole document	1-111
Y	US 2003/0096777 A1 (BESTERMAN et al) 22 May 2003 (22.04.2003), whole document	1-111
Y	US 2003/0114525 A1 (KAMMER et al) 19 June 2003 (19.06.2003), whole document	1-111



Further documents are listed in the continuation of Box C.

See patent family annex.

* Special categories of cited documents:

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier application or patent published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"&"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

02 March 2005 (02.03.2005)

Date of mailing of the international search report

06 APR 2005

Name and mailing address of the ISA/US

Mail Stop PCT, Attn: ISA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Authorized officer

Andrew D Kosar

Telephone No. (571)272-1600

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US04/26161

C. (Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 2003/0144340 A1 (LONG et al) 31 July 2003 (31.07.2003), whole document	1-111
Y	BUTLER, L.M. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up regulates thioredoxin-binding-protein-2, and down-regulates thioredoxin. Proc. Natl. Acad. Sci. USA. September 3, 2002. Vol. 99, No. 18, Pages 11700-11705.	1-111
Y	CASTRO-GALACHE, M.D. Susceptibility of multidrug resistance tumor cells to apoptosis induction by histone deacetylase inhibitors. Int. J. Cancer. 2003, Vol. 104, Pages 579-586.	1-111
Y	HENDERSON, C. Role of caspases, Bid, and p53 in the apoptotic response triggered by histone deacetylase inhibitors trichostatin-A (TSA) and suberoylanilide hydroxamic acid (HSA). J. Biol. Chem. April 4, 2003, Vol. 278, No. 14, Pages 12579-12589.	1-111
Y	ZHU, W.-G. The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr. Med. Chem.- Anti-Cancer Agents. 2003, Vol. 3, No. 3, Pages 187-199.	1-111
Y	PEART, M.J. Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Research. August 1, 2003, Vol. 63, Pages 4460-4471.	1-111
Y,P	KELLY, W.K. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clinical Cancer Research. September 1, 2003, Vol. 9, No. 10, Pages 35787-3588	1-111
Y,P	KIM, M.S. Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA. Cancer Research. November 1, 2003, Vol. 63, Pages 7291-7300.	1-111